Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Gilead Sciences in a report ...

Stock analysts at Leerink Partnrs dropped their Q2 2025 earnings estimates for shares of Encompass Health in a note issued to investors on Tuesday, February 11th. Leerink Partnrs analyst W. Mayo now ...

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class ...

Last year, Bristol Myers Squibb devoted half a page of its annual report to its diversity, equity and inclusion efforts, ...